ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
2026 Nuclear Energy Conference & Expo (NECX)
August 24–27, 2026
Dallas, TX|Hilton Anatole
Latest Magazine Issues
Jun 2026
Jan 2026
2026
Latest Journal Issues
Nuclear Science and Engineering
August 2026
Nuclear Technology
July 2026
Fusion Science and Technology
Latest News
Launching into tomorrow: NRIC guides new era of research and deployment
In June 2025, the Department of Energy announced the Reactor Pilot Program, an authorization pathway that allowed reactor developers to partner with the DOE to get first-of-a-kind (FOAK) reactors built and tested. Soon after, the DOE rolled out a complementary Fuel Line Pilot Program, which aimed to fast-track fuel projects. In all, 20 projects were accepted into the new programs.
George A. Miller, Jr., Nolan E. Hertel, Bernard W. Wehring, John L. Horton
Nuclear Technology | Volume 103 | Number 3 | September 1993 | Pages 320-331
Technical Paper | Radiation Biology and Medicine | doi.org/10.13182/NT93-A34855
Articles are hosted by Taylor and Francis Online.
A computer study of the dose distribution for gadolinium neutron capture therapy is carried out to determine its feasibility. Gadolinium is a potential neutron capture therapy (NCT) agent that produces gamma radiation, conversion electrons, and Auger electrons. The dose distribution from neutrons, neutron-induced gammas, and the reaction products from neutron capture in gadolinium were modeled using the Los Alamos National Laboratory Monte Carlo neutron photon computer code. The results of these calculations are that gadolinium has promise as an NCT agent. Using two parallel opposed epithermal neutron beams for a tumor at an 8.0-cm depth with a gadolinium loading of 100 µg/g, the tumor to peak normal tissue dose was determined to be 1.48.